Drugs /

arx788

Back to Drugs List

Overview

NCI Definition [1]:
An antibody-drug conjugate (ADC) composed of a monoclonal antibody targeting human epidermal growth factor receptor 2 (EGFR2; HER2) site-specifically conjugated, via the non-natural amino acid linker para-acetyl-phenylalanine (pAcF), to the auristatin analog and potent microtubule inhibitor monomethyl auristatin F (MMAF), with potential antineoplastic activity. Upon administration of anti-HER2 ADC ARX788, the antibody moiety targets and binds to HER2 on tumor cells. Upon antibody/antigen binding and internalization, MMAF binds to and inhibits tubulin polymerization, which results in G2/M phase arrest and tumor cell apoptosis. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types. The site-specific conjugation of the cytotoxic agent to the antibody improves the biophysical properties of ARX788, increases payload stability and optimizes its efficacy.

Clinical Trials

View Clinical Trials for arx788

Arx788 has been investigated in 3 clinical trials, of which 2 are open and 1 is closed. Of the trials investigating arx788, 2 are phase 1 (1 open) and 1 is phase 2 (1 open).

ERBB2 Amplification, HER2 Overexpression, and HER2 Positive are the most frequent biomarker inclusion criteria for arx788 clinical trials.

Breast carcinoma, malignant solid tumor, and gastric carcinoma are the most common diseases being investigated in arx788 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Arx788
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Arx788
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating arx788 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
anti-her2 antibody-drug conjugate arx788, anti-her2 adc arx788, anti-her2 adc arx788, adc arx788, anti-her2 antibody-drug conjugate arx788, arx-788
NCIT ID [1]:
C123917

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.